MedTrace Logo

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

NCT07110363 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.

Conditions

Interventions

DRUG

BT02

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors & Collaborators

  • Biotroy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Shun Lu, MD · Shanghai Chest Hospital of Shanghai Jiao Tong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2027-03-31
Completion
2027-05-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07110363 on ClinicalTrials.gov